Very true that financial remuneration is almost always involved in the marketing of medical products by medical professionals. I also agree, the truth definitely is reflected in the sales and recurring revenue numbers - I don't doubt the existing iTrack customers will transition over to the Advance. I haven't compared the revenue per customer across the competition, if you have the numbers handy that would be very helpful.
Very true that financial remuneration is almost always involved...
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
-0.005(1.89%) |
Mkt cap ! $59.48M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.5¢ | 25.5¢ | $17.72K | 68.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 291685 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 37241 | 1 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
26.0¢ |
Change
-0.005 ( 1.89 %) |
||||
| Open | High | Low | Volume | ||
| 26.0¢ | 26.5¢ | 26.0¢ | 72451 | ||
| Last updated 14.26pm 08/05/2024 ? | |||||
| EYE (ASX) Chart |